CoChat

Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids

RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., MARKS, V. · 1999 · Clinical Science

The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.

Abstract

Two studies were performed to assess the entero-insular axis in simple obesity and the possible effect of variations in the level of circulating non-esterified fatty acids (NEFA) on one of the components of the entero-insular axis, glucagon-like peptide-1 [(7–36) amide]. In the first study, we compared the entero-pancreatic hormone response to oral carbohydrate in obese and lean women. Obese subjects demonstrated hyperinsulinaemia and impaired glucose tolerance but this was not associated with an increased secretion of either glucose-dependent insulinotropic polypeptide or glucagon-like peptide-1 (GLP-1). These findings therefore provide no support for the hypothesis that overactivity of the entero-insular axis contributes to the hyperinsulinaemia seen in obesity. Indeed, the plasma GLP-1 response to carbohydrate was markedly attenuated in obese subjects, confirming previous observations. In the second study, in which carbohydrate-stimulated GLP-1 responses were again evaluated in obese and lean women, circulating NEFA levels were modulated using either heparin (to increase serum NEFA) or acipimox (to reduce serum NEFA). Treatment with acipimox resulted in complete suppression of NEFA levels and in a markedly higher GLP-1 response than the response to carbohydrate alone or to carbohydrate plus heparin. We suggest that higher fasting and postprandial NEFA levels in obesity may tonically inhibit nutrient-mediated GLP-1 secretion, and that this results in attenuation of the GLP-1 response to carbohydrate. However, although serum NEFA levels post-acipimox were similarly suppressed in both lean and obese subjects, the GLP-1 response was again significantly lower in obese subjects, suggesting the possibility of an intrinsic defect of GLP-1 secretion in obesity. The reduction of GLP-1 levels in obesity may be important both in relation to its insulinotropic effect and to its postulated role as a satiety factor.

Overview

Integrity signals

Registry

Crossref · 10.1042/cs0960335

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 47

Metadata

Authors
RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V.
Affiliations
  • Epsom Hospital (GB)
  • University of Surrey (GB)
Venue
Clinical Science
Published
1999-04-01
Volume
96
Issue
4
Pages
335-342
ISSN
  • 0143-5221 (ISSN-L)
  • 1470-8736
OpenAlex
W2013878695
Cited by
47
References
31
Citations by year
2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2019: 5 · 2018: 2 · 2017: 1 · 2015: 1 · 2014: 2 · 2012: 1
FWCI
1.61
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Science (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucagon-like peptide-1, free fatty acids, enteroinsular axis, obesity, hyperinsulinemia, impaired glucose tolerance, acipimox, heparin, glucose-dependent insulinotropic polypeptide, GLP-1 secretion, satiety, insulin secretion
MeSH terms
Adult, Analysis of Variance, Dietary Carbohydrates, Glucagon-Like Peptides, Fatty Acids, Nonesterified, Female, Gastric Inhibitory Polypeptide, Glucagon, Glucose Tolerance Test, Heparin, Humans, Insulin, Models, Biological, Obesity, Peptide Fragments, Pyrazines, Triglycerides, Case-Control Studies, Neurotransmitter Agents, Postprandial Period, Area Under Curve, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.